Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
RPG Life Sciences Limited ( (IN:RPGLIFE) ) has provided an announcement.
RPG Life Sciences reported a 4.2% year-on-year rise in revenue to Rs 180 crore for the third quarter ended 31 December 2025, with an EBITDA margin of 24%, while nine-month FY26 revenue grew 4% to Rs 530.6 crore, underscoring steady operational momentum despite a slight sequential dip in quarterly revenue. Management highlighted that the Domestic Formulations business outpaced the broader Indian Pharmaceutical Market, growing 11.8% in the first nine months of FY26 versus IPM growth of 8.2%, and reiterated the company’s strategy of disciplined execution, portfolio optimisation and building a resilient, innovation-led, people-first organisation aimed at creating sustainable value for patients, partners and stakeholders.
More about RPG Life Sciences Limited
RPG Life Sciences Limited is an integrated research-based pharmaceutical company operating in domestic and international markets, with a presence in branded formulations, global generics and synthetic APIs. The company focuses on producing a wide range of quality, affordable medicines, and its brands are widely trusted by healthcare professionals and patients.
Average Trading Volume: 1,523
Technical Sentiment Signal: Buy
Current Market Cap: 35.32B INR
Find detailed analytics on RPGLIFE stock on TipRanks’ Stock Analysis page.